If depletion of SRRM3 in human and rat β-cell lines, as well as mouse pancreatic islets, or the use of antisense oligonucleotides to inhibit specific IsletMICs, can result in inappropriate insulin secretion, this suggests that IsletMICs are present at low levels in patients with T2DM; hence, upregulation of IsletMICs levels is a potential therapeutic strategy [159]. This evidence concerns the gene INS and type 2 diabetes mellitus.